Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Completed · Phase 2
Conditions studied: Kidney Cancer
In brief
RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of liposomal tretinoin plus interferon alfa in treating patients who have metastatic kidney cancer.
Key facts
- Study ID
- NCT00003656
- Run by
- Weill Medical College of Cornell University
- People needed
- 26
- Starts
- 1999-01-01
- Expected to finish
- 2008-05-01
- Last updated by the study team
- 2022-03-18
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States
- Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.